http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0220054-A3
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D295-096 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D213-65 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D295-096 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D213-65 |
| filingDate | 1986-10-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 1987-12-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-0220054-A3 |
| titleOfInvention | Ethanolamine derivatives |
| abstract | The present invention provides compounds of the ngeneral formula (I) n nwherein nAr represents a phenyl group optionally substituted by one nor more substituents selected from halogen atoms, or the ngroups C 1-6 alkyl, nitro, -(CH₂) q R, [where R is hydroxy, nC 1-6 alkoxy, -NR³R⁴ (where R³ and R⁴ each represents a nhydrogen atom, or a C 1-4 alkyl group, or -NR³R⁴ forms a nsaturated heterocyclic amino group which has 5-7 ring nmembers and optionally contains in the ring one or more natoms selected from -O- or -S- or a group -NH- or n-N(CH₃)-), -NR⁵COR⁶ (where R⁵ represents a hydrogen atom nor a C 1-4 alkyl group, and R⁶ represents a hydrogen atom nor a C 1-4 alkyl, C 1-4 alkoxy, phenyl or -NR³R⁴ group), n-NR⁵SO₂R⁷ (where R⁷ represents a C 1-4 alkyl, phenyl or n-NR³R⁴ group), -COR⁸ (where R⁸ represents hydroxy, C 1-4 nalkoxy or -NR³R⁴), -SR⁹ (where R⁹ is a hydrogen atom, or a nC 1-4 alkyl or phenyl group), -SOR⁹, -SO₂R⁹, or -CN, and q nrepresents an integer from 0 to 3], or -O(CH₂) t R¹⁰ [where nR¹⁰ represents a hydroxy or C 1-4 alkoxy group, and t is nan integer 2 or 3], or Ar is a phenyl group substituted nby an alkylenedioxy group of formula -O(CH₂) p O-, where np represents an integer 1 or 2; nR¹ and R² each represents a hydrogen atom or a C 1-3 alkyl ngroup with the proviso that the sum total of carbon atoms nin R¹ and R² is not more than 4; n n nX represents a bond or a C 1-7 alkylene, C 2-7 alkenylene nor C 2-7 alkenylene chain and nY represents a bond or a C 1-6 alkylene, C 2-6 alkenylene or nC 2-6 alkynylene chain with the proviso that the sum total nof carbon atoms in X and Y is 2-10; n n[where Q¹ represents the group CH₂R²³ (where R²³ nrepresents C 1-3 alkoxy, methanesulphonyl or cyano) or the ngroup -CH₂NHR¹¹ (where R¹¹ represents R¹²CO-, R¹²NHCO-, nR¹²R¹³NSO₂- or R¹⁴SO₂-, where R¹² and R¹³ each represent a nhydrogen atom or a C 1-3 alkyl group, and R¹⁴ represents a nC 1-3 alkyl group), or the group -NR¹⁵R¹⁶ (where R¹⁵ nrepresents a hydrogen atom or a C 1-4 alkyl group, and R¹⁶ nrepresents a hydrogen atom or a C 1-4 alkyl group or, when nR¹⁵ is a hydrogen atom, R¹⁶ also represents a C 1-4 alkoxyncarbonyl group)], or Q represents the group n nsubstituted by a hydroxy group and optionally also by a nhalogen atom; nand physiologically acceptable salts and solvates (e.g. nhydrates)thereof. n The compounds have a stimulant action at β₂-adrenonreceptors and may be used in the treatment of diseases nassociated with reversible airways obstruction such as nasthma and chronic bronchitis. |
| priorityDate | 1985-10-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 30.